CADX: Summary for Cadence Pharmaceuticals, Inc. - Yahoo! Singapore Finance

	Sign In [New User? Sign Up]	Finance Home \|Help

Wednesday, February 10, 2010, 7:37pm SGT - The Singapore stock market is closed.

To create a watchlist or portfolio of shares, Register

FINANCE HOME PAGE

INVESTING

FINANCE NEWS

Cadence Pharmaceuticals Inc. (CADX)

At 5:00AM SGT: 10.34 USD 0.00 (0.00%)

MORE ON CADX

Quotes

Summary

Charts

News & Info

Company

Analyst Coverage

Ownership

Financials

Cadence Pharmaceuticals, Inc. (NGM:CADX) Delayed quote data

Last Trade:	10.34 USD
Trade Time:	5:00AM SGT
Change:	0.00 (0.00%)
Prev Close:	10.34
Open:	N/A
Bid:	N/A
Ask:	N/A
1y Target Est:	13.00

Day's Range:	N/A - N/A
52wk Range:	5.68 - 12.68
Volume:	0
Avg Vol (3m):	374,216
Market Cap:	521.66M
P/E (ttm):	N/A
EPS (ttm):	-0.97
Div & Yield:	N/A (N/A%)

1d 5d 3m 6m 1y 2y 5y

Use Y! Toolbar to track stocks

Add CADX to Portfolio

Download Data

HEADLINES

•	Monday Options Recap: Volatility Eases
	at Seeking Alpha (Tue 4:55am)

•	[$$] A Pain-Free Investment
	at RealMoney by TheStreet.com (Wed, Jan 20)

•	Cadence Pharma downgraded by Oppenheimer
	Briefing.com (Mon, Nov 16)

•	[$$] Small Stocks Gain on Week
	at The Wall Street Journal Online (Sat, Nov 14)

•	CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
	EDGAR Online (Sat, Nov 14)

•	FDA Delays Cadence Drug Review: BioBuzz
	at TheStreet.com (Fri, Nov 13)

•	FDA extends review of Cadence's IV drug Acetavance
	AP (Fri, Nov 13)

•	Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
	PR Newswire (Fri, Nov 13)

•	CADENCE PHARMACEUTICALS INC Financials
	EDGAR Online Financials (Wed, Nov 11)

•	3 Companies Looking for Gratitude Early
	at Motley Fool (Wed, Nov 11)

•	CADENCE PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements a
	EDGAR Online (Fri, Nov 6)

More Headlines for CADX...

ANALYST

EPS Est (next year) (Dec-09) :	-0.95
EPS Est (in 2 years) (Dec-10) :	-1.27
Avg Rec (current)*:	2.1
PEG Ratio:	N/A

* (Strong Buy) 1.0 - 5.0 (Strong Sell)

Analyst Opinion - Estimates

BUSINESS SUMMARY

Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada.

Full Company Profile

Add to Portfolio

Email to a Friend

•